What is Bicycle Therapeutics Ltd (BCYC) stock price today?

Bicycle Therapeutics Ltd (BCYC) currently trades at $4.72 per share. The stock has a market capitalization of $337.89M and a P/E ratio of —x.

Is BCYC stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Bicycle Therapeutics Ltd has a Smart Value Score of 43/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Bicycle Therapeutics Ltd's revenue and earnings?

Bicycle Therapeutics Ltd has trailing twelve-month (TTM) revenue of $72.59M with profit margins of 0.00%. Earnings per share (EPS) is $-3.16.

Is BCYC stock overvalued or undervalued?

Based on our DCF model, Bicycle Therapeutics Ltd's intrinsic value is $6.18, representing a margin of safety of 10.36%. The stock currently trades at a P/E of —x.

BCYC

Bicycle Therapeutics Ltd

NASDAQ: BCYC · HEALTHCARE · BIOTECHNOLOGY

$4.72

-0.21% today

Updated 2026-04-30

Market cap

$337.89M

P/E ratio

—

P/S ratio

4.66x

EPS (TTM)

$-3.16

Dividend yield

—

52W range

$4 – $10

Volume

0.5M

Market cap

$337.89M

P/E ratio

—

P/S ratio

4.66x

EPS (TTM)

$-3.16

Dividend yield

—

52W range

$4 – $10

Volume

0.5M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

8.0

Growth

5.0

Quality

C+

2.5

Profitability

5.3

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$12.56

+166.10%

12-Month target

—

Intrinsic (DCF)

$6.18

Margin of safety

+10.36%

2 Strong Buy5 Buy4 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 1,193.00% QoQ

+ 10.36% below intrinsic value

Risks

- Thin margins at 0.00%

- Negative free cash flow $-20.79M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$14.46M	$26.98M	$35.27M	$72.59M	$72.59M
Net income	$-112.72M	$-180.66M	$-169.03M	$-218.96M	$-20.15M
EPS	—	—	—	—	$-3.16
Free cash flow	$-105.10M	$-63.56M	$-165.96M	$-252.03M	$-20.79M
Profit margin	-779.35%	-669.72%	-479.18%	-301.66%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-06	THOMPSON, TRAVIS ALVIN	Sale	102	$5.05
2026-04-06	SKYNNER, MICHAEL	Sale	525	$5.05
2026-04-06	PERRY, JENNIFER SCOTT	Sale	333	$5.04

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BCYC	$337.89M	43	8.0	2.5	5.3	5.0	+10.36%	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Bicycle Therapeutics Ltd trades at $4.72. Our Smart Value Score of 43/100 indicates the stock is fair. TTM revenue stands at $72.59M. Our DCF model estimates intrinsic value at $6.18.

Frequently asked questions

What is Bicycle Therapeutics Ltd's stock price?

Bicycle Therapeutics Ltd (BCYC) trades at $4.72.

Is Bicycle Therapeutics Ltd overvalued?

Smart Value Score 43/100 (Grade D, Sell). DCF value $6.18.

What is the price target of Bicycle Therapeutics Ltd (BCYC)?

The analyst target price is $12.56, representing +166.1% upside from the current price of $4.72.

What is the intrinsic value of Bicycle Therapeutics Ltd (BCYC)?

Based on our DCF model, intrinsic value is $6.18, a +10.4% margin of safety versus $4.72.

What is Bicycle Therapeutics Ltd's revenue?

TTM revenue is $72.59M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio4.66x

ROE-31.20%

Beta1.65

50D MA$5.08

200D MA$6.72

Shares out0.05B

Float0.00B

Short ratio—

Avg volume0.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BCYC vs LLY →BCYC vs JNJ →BCYC vs ABBV →Stock screener →